Connie is an Associate on the healthcare team at F-Prime Capital. She works closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Prior to joining F-Prime Capital, Connie was a Consultant with IQVIA in New York, where she advised biopharmaceutical companies on commercial, development, and portfolio strategy topics.
Connie received her B.S.E. in Bioengineering from the University of Pennsylvania.
Geneception is a fully-integrated gene and cell therapy based in Hangzhou and Shanghai, China. Founded by F-Prime Capital, Eight Roads Ventures China and Lilly Asia Ventures in 2018, Geneception’s mission is to become a preeminent gene and cell therapy company, working to deliver world-class therapeutics for patients in China and globally.